Abstract
Importance Children are less likely than adults to have severe outcomes from SARS-CoV-2 infection and the corresponding risk factors are not well established.
Objective To identify risk factors for severe disease in symptomatic children hospitalized for PCR-positive SARS-CoV-2 infection.
Design Cohort study, enrollment from February 1, 2020 until May 31, 2021
Setting 15 children’s hospitals in Canada, Iran, and Costa Rica
Participants Patients <18 years of age hospitalized with symptomatic SARS-CoV-2 infection, including PCR-positive multisystem inflammatory syndrome in children (MIS-C)
Exposures Variables assessed for their association with disease severity included patient demographics, presence of comorbidities, clinical manifestations, laboratory parameters and chest imaging findings.
Main Outcomes and Measures The primary outcome was severe disease defined as a WHO COVID-19 clinical progression scale of ≥6, i.e., requirement of non-invasive ventilation, high flow nasal cannula, mechanical ventilation, vasopressors, or death. Multivariable logistic regression was used to evaluate factors associated with severe disease.
Results We identified 403 hospitalizations. Median age was 3.78 years (IQR 0.53-10.77). At least one comorbidity was present in 46.4% (187/403) and multiple comorbidities in 18.6% (75/403). Severe disease occurred in 33.8% (102/403). In multivariable analyses, presence of multiple comorbidities (adjusted odds ratio 2.24, 95% confidence interval 1.04-4.81), obesity (2.87, 1.19-6.93), neurological disorder (3.22, 1.37-7.56), anemia, and/or hemoglobinopathy (5.88, 1.30-26.46), shortness of breath (4.37, 2.08-9.16), bacterial and/or viral coinfections (2.26, 1.08-4.73), chest imaging compatible with COVID-19 (2.99, 1.51-5.92), neutrophilia (2.60, 1.35-5.02), and MIS-C diagnosis (3.86, 1.56-9.51) were independent risk factors for severity. Comorbidities, especially obesity (40.9% vs 3.9%, p<0.001), were more frequently present in adolescents ≥12 years of age. Neurological disorder (3.16, 1.19-8.43) in children <12 years of age and obesity (3.21, 1.15-8.93) in adolescents were the specific comorbidities associated with disease severity in age-stratified adjusted analyses. Sensitivity analyses excluding the 81 cases with MIS-C did not substantially change the identified risk factors.
Conclusions and Relevance Pediatric risk factors for severe SARS-CoV-2 infection vary according to age and can potentially guide vaccination programs and treatment approaches in children.
Question What are the risk factors for severe disease in children hospitalized for PCR-positive SARS-CoV-2 infection?
Findings In this multinational cohort study of 403 children, multiple comorbidities, obesity, neurological disorder, anemia, and/or hemoglobinopathy, shortness of breath, bacterial and/or viral coinfections, chest imaging compatible with COVID-19, neutrophilia, and MIS-C diagnosis were independent risk factors for severity. The risk profile and presence of comorbidities differed between pediatric age groups, but age itself was not associated with severe outcomes.
Meaning These results can inform targeted treatment approaches and vaccine programs that focus on patient groups with the highest risk of severe outcomes.
Competing Interest Statement
Manish Sadarangani has been an investigator on projects funded by GlaxoSmithKline, Merck, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo and VBI Vaccines. All funds have been paid to his institute, and he has not received any personal payments. Jesse Papenburg reports grants to his institution from MedImmune, Sanofi Pasteur and AbbVie, and personal fees from AbbVie, all outside of the submitted work. Shaun K Morris has received honoraria for lectures from GlaxoSmithKline and was a member of an ad hoc advisory board for Pfizer Canada, both outside of the submitted work.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The following Ethics committees/IRBs all gave approval for this work: Comite Etico Cientifico Hospital Nacional de Ninos, Costa Rica; Iran University of Medical Sciences Ethics Review Committee, Iran; The Hospital for Sick Children Research Ethics Board, Canada; Pediatric Panel of the Research Ethics Board of the Research Institute of the McGill University Health Centre, Canada; Conjoint Health Research Ethics Board, University of Calgary, Canada; Children's Hospital of Eastern Ontario Research Ethics Board, Canada; University of British Columbia Children's and Women's Research Ethics Board, Canada; Health Research Ethics Board, University of Manitoba, Canada; University of Saskatchewan Biomedical Research Ethics Board, Canada; Hamilton Integrated Research Ethics Board, Canada; Centre Hospitalier Universitaire de Quebec-Universite Laval, Canada;,Health Research Ethics Board, University of Alberta, Canada; CHU Sainte-Justine, Universite de Montreal, Canada; Lawson Health Research Institute, Canada; Trillium Health Partners Research Ethics Board, Canada; Queen's University Health Sciences and Affiliated Teaching Hospitals Research Ethics Board, Canada; IWK Research Ethics Board, Canada
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
- the error bars in Figure 2 (lower 95% CI) have been corrected - The author contribution statement has been revised
Data sharing statement
The corresponding authors will consider data sharing requests that are accompanied by a study protocol and approval by an independent research ethics board.
